EUVIMEDObjevte EUVIMED
Editorial

Clinical insights: Regenerative therapies in equine practice: Top 10 EVJ papers 2019–2024

Lynn Pezzanite iD

Equine Veterinary Journal · 2024

DOI: 10.1111/evj.14136 ↗

At a glance

Editorial in Equine Veterinary Journal, 2024. Written by Lynn Pezzanite. Institution: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA. Major MEDLINE topics: Horse Diseases. 43 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

In the past two decades, the field of veterinary regenerative medicine has advanced considerably, with multiple therapies available to equine practitioners to treat joint and soft tissue disorders as well as a variety of other conditions such as wounds, ophthalmic or theriogenology indications. The term 'regenerative therapies' is a broad definition for innovative medical therapies that enable the body to repair, replace, restore and regenerate damaged or diseased cells, tissues and organs, while 'biological products' are those made from living material (human, animal, plant, microorganisms) used to treat or prevent disease. Options available to clinicians in equine practice include point-of-care blood or tissue-derived products (autologous) including platelet-rich plasma (PRP), autologous conditioned serum (ACS or interleukin receptor antagonist protein/IRAP), autologous protein solution (APS), bone marrow aspirate concentrate (BMAC or stromal vascular fraction) or cultured stromal cell-based products (autologous or allogeneic). Treatments in this area are rapidly evolving and clinicians are often asked for guidance as to the selection of one treatment over another for a specific clinical indication. However, the true efficacy of regenerative therapies remains controversial in some instances due to lack of rigour in clinical study design, lack of demonstrated consistency in product formulation and lack of regulatory oversight that would assure appropriate standards. The Equine Veterinary Journal (EVJ) papers included in the editorial review below have been assembled in a 'Special Collection', which aims to identify the 'Top 10' recent publications from EVJ (2019–2024) (Table 1) related to regenerative therapies and to highlight adjacent literature in other journals, which may aid practitioners in this field. The first manuscript in our collection, by Zanotto and Frisbie (2022), describes a survey of the American Association of Equine Practitioners updating on current practices in joint therapy, highlighting changes in the past 10 years.1 A total of 407 completed surveys were returned, with the majority of respondents (90.9%) indicating that they spend most of their time (>75%) dedicated to equine practice, and most commonly working with racehorses (52.4%) and hunter/jumper (50.6%) disciplines. The findings overall indicated clear differences in the use of joint therapies over time, with an increase in prevalence of biological therapies since the previous survey 10 years prior.2 The majority of respondents (87%) did report that they had treated patients who benefited from intra-articular biologic therapies. The most common reason cited for selecting a biological therapy over corticosteroids for intra-articular use was perceived long-term efficacy (45.7%), followed by safety (19.4%), client request (10.8%) and short-term efficacy (5.6%). The majority of respondents (83.3%) reported using ACS or interleukin receptor antagonist protein (IRAP), followed by PRP (72.5%), APS (53.8%), stromal cell therapy (53.7%) and BMAC (22.4%). The likelihood of respondents reporting having used ACS in particular was substantially higher in 2019 than in the previous survey performed in 2009.1, 2 The three most commonly reported factors influencing the selection of biological therapy were scientific data on efficacy, cost, and severity or chronicity of the condition to be treated. Biologic therapies were more commonly used in cases that were not previously responsive to corticosteroid treatment or when treating diseased soft tissues within a joint such as meniscus or ligament. Respondents reported the perspective that the joints that responded best to biological therapies were the stifle (33.2%), fetlock (23.6%) and coffin joints (22.6%). The authors went on to discuss and summarise that these findings highlight the importance of a cost-effectiveness analysis among biological therapies and other commonly used treatments such as corticosteroids and hyaluronic acid for long-term management of joint disease in performance horses. These findings reflect both similarities and differences to another recent survey of orthobiologic use of the American College of Veterinary Surgeons (ACVS) and American College of Veterinary Sports Medicine and Rehabilitation (ACVSMR) diplomates.3 In this study, 154 surveys were analysed, with respondents most commonly treating sport horses (44%) followed by Western performance (24%), racehorses (15%), pleasure horses (9%) and show horses (8%). The most common reasons for selecting one biologic treatment over another were based on scientific articles and data demonstrating efficacy (56%), personal experience (20%) and due to inefficacy of previous treatments evaluated (10%). Overall, PRP was the most commonly used biologic therapy by respondents (87.5%), followed by ACS (79.7%), bone marrow-derived mesenchymal stromal cell (MSC; 72.1%), APS (46.2%) and adipose-derived MSCs (19.5%). An additional 24% of respondents indicated that they used stromal cell therapy that was neither adipose- nor bone marrow-derived, but the cell source was not specified. Regarding indication or route of administration, respondents reported MSCs and PRP being more commonly administered intralesionally, while ACS and APS were more frequently administered intralesionally. Treatment of ACS was repeated commonly within 2 weeks of initial injection (48.1%), while MSCs (43.3%) and PRP (38%) were re-injected less frequently at 1–2 months after initial injection. APS was typically repeated more than 4 months after initial injection (39.6%). Local inflammation and expense were the most common adverse effects and limitation to use discussed. Protocols for repeated administration varied widely, and the lack of consensus regarding the timing of first injection following diagnosis or optimal treatment interval for repeated injections was discussed further. Overall, the authors discussed that, similarly to that reported by Zanotto and Frisbie1 as well as another recent international survey of rehabilitation modalities by equine veterinarians,4 the findings of this survey reflect a general increase in the use of biologic therapies over the past decade with high prevalence of the use of ACS and PRP. Their findings further suggested a similar level of use among large animal specialists, regardless of duration in practice or practice type, which was attributed to increased commercial availability and literature surrounding biological therapies for musculoskeletal disease, specifically in recent years. The information collected by these surveys provide a baseline of current understanding of common practices surrounding the use of equine biological products for musculoskeletal disease at this time and help to support the continued use and investigation of these products. However, relatively little work has been done to evaluate and compare the biological activities of these compounds more fully or to support optimal processing and storage conditions, recommended dosages, or evidence-based protocols for the application of biologics clinically. Therefore, the decision on which biologic to use in a specific disease condition is often based on incomplete information on the specific pathological physiology. Larger case-controlled studies and clinical trials are warranted to determine treatment efficacy, optimal treatment intervals and to compare available therapies for specific indications. Below, we will further discuss the recent literature for each of the most commonly used biologic therapies (PRP, ACS, MSC) individually. PRP has been used for the longest time and is the most extensively studied of the orthobiologics available. It exerts an effect based on platelet α-granule release of growth factors and chemokines, cytokines, and fibrinogen in plasma that stimulates macrophage chemotaxis, angiogenesis, proliferation, fibroblast migration and collagen synthesis to direct cellular processes integral to healing. In the second paper in our collection, Peng et al. (2024) aimed to systematically review the current evidence on PRP products used for osteoarthritis and septic arthritis in equine practice, as well as the efficacy of PRP products for the treatment of OA using a meta-analysis of the available literature (2013–2023).5 Randomised controlled trials, non-randomised trials and controlled laboratory studies that used at least one type of PRP product were included. This study identified a total of 21 publications by systematic review and five for meta-analysis, which evaluated various different types of PRP products. The authors concluded that most of the studies were associated with a high risk of bias, but that the overall estimated effect indicated improvement in groups treated with PRP products for equine OA, and that PRP had potential in treating septic arthritis. These conclusions were noted to be tempered by the limited number of randomised controlled studies and high variability between the types of PRP products in terms of platelet and leukocyte count. To better evaluate PRP efficacy, a recognised classification system of products and utilisation of randomised, blinded, equivalency or non-inferiority trials would be necessary. ACS, also known as interleukin-1 receptor antagonist protein (IRAP), was developed to counteract the effects of the cytokine interleukin-1 (IL-1ß) produced in sites of inflammation, such as joints with osteoarthritis. In the third paper in our collection, Lofgren et al. (2023) evaluated the effects of ACS further in an in vitro experiment where chondrocytes stimulated with IL-1ß and cartilage explants with mild osteoarthritis were treated with either equine serum, serum incubated for 24 h or serum incubated for 24 h using a commercially available ACS container.6 Chondrocytes were then evaluated using microarray, polymerase chain reaction, and for matrix metallopeptidase-13, and cartilage explants were assessed using the OARSI grading scale for histological evaluation of articular cartilage. In chondrocytes, inflammation- and cartilage matrix degradation-related genes, as well as growth factor signalling genes, were upregulated in all treatment groups versus untreated controls, while in explants, the histological OARSI scores did not differ between groups. This study is the first to assess the global gene expression associated with inflammation and cartilage matrix degradation in IL-1ß-stimulated chondrocytes and histological staging of OA cartilage explants to evaluate treatment effect. Additionally, the investigators found that serum incubated for 24 h (in the absence of using the commercial kit) contained significantly higher levels of IL-1Ra than ACS, which questions the reported necessity to use commercial systems to achieve elevated levels of IL-1Ra. However, this study did not indicate that either the incubated serum nor commercial ACS product alleviates IL-1ß induced responses in chondrocyte pellets or led to morphological improvement in osteoarthritic cartilage explants. The results do not support a beneficial disease-modifying effect of ACS on articular cartilage, although the information gleaned from these in vitro models cannot be directly translated to the in vivo scenario in which ACS is commonly used. Future studies to determine efficacy of ACS specifically to treat joint pain and its potential ability to reduce clinical lameness are still warranted. Stromal cells are undifferentiated cells capable of self-renewal and differentiation into specific lineages. Multipotent cells (e.g., mesenchymal, haematopoietic) give rise to more than one cell type but are often restricted to a single germ layer, while pluripotent cells (e.g., embryonic, fetal-derived embryonic-like, or induced pluripotent) give rise to all cell types of the body from all three germ layers. Sources of stromal cells in equine practice include bone marrow, adipose, blood, umbilical cord blood, amniotic tissue, dental pulp and synovial fluid or synovial lining. Typical reported dose ranges are from 10 to 30 million stem cells per joint or site. However, knowledge gaps remain regarding optimal cell number, timing of administration during inflammation, optimal pre-activation techniques to direct differentiation or cytokine secretion and use of autologous versus allogeneic preparations. Recent studies have focused on optimising cell preparations to increase efficacy or decrease antigenicity for allogeneic use7-9 and to expand clinical use to include extracellular vesicle-based formulations.10 In this section on stromal cell therapy, we will highlight recent evidence for efficacy in equine practice, investigation of immune licensing of MSC to enhance their immunomodulatory and antimicrobial effects and discussion of autologous versus allogeneic use, and future directions for cellular-based therapies including extracellular vesicle (EV)-based approaches or minimally manipulated biologic therapeutic options. Evidence for cellular therapy efficacy: Preclinical studies support modest improvement in healing with MSC therapy for tendon lesions,11, 12 cartilage grafting13 and intra-articular14-16 and more recently for their antimicrobial properties to treat infection.17-19 Clinical retrospective studies have provided evidence for reduced re-injury rate in National Hunt racehorses treated with MSCs for superficial digital flexor tendinopathy injury,20 and that a higher percentage of horses with stifle injury, particularly meniscal injury, returned to work following intra-articular MSC injection.16 A recent systematic review and meta-analysis of the use of stem cells and platelet-rich plasma for the treatment of naturally occurring equine tendon and ligament injuries indicated that MSCs and MSCs administered concurrently with PRP provided a reduced risk of re-injury.21 This study did not reveal an overall increase in the likelihood of return to performance with any of the biologic treatments assessed; however, the authors concluded that these findings should be interpreted with consideration of the heterogeneity of findings, high risk of bias and poor study design in the majority of studies reported. In the fourth paper in our series, Hansen et al. (2024) built upon this body of work to evaluate the racing performance of Thoroughbred racehorses with suspensory ligament branch desmitis (SLBD) treated with mesenchymal stem cells (2010–2019).22 All horses were treated with allogeneic stem cells injected locally at the time of diagnosis and subsequently received three to four treatments with autologous bone marrow-derived MSCs. The authors concluded that treatment with MSCs resulted in the majority of Thoroughbred racehorses (71%) racing post treatment, with factors including having previously raced pre-injury and being male also positively associated with racing post-injury. In horses that raced post-injury, the number of races, earnings and earnings per start did not differ from pre-injury. In the fifth paper in our series, Salz et al. (2023) further evaluated the association between treatment with either autologous bone marrow-derived (BM) MSC, allogeneic adipose-derived MSC or controlled exercise rehabilitation in 213 racehorses diagnosed with superficial digital flexor tendonitis (SDFT) with return to racing and completion of at least five races post-injury.23 Follow-up was a minimum of 2 years after return to race training. Compared with controlled exercise rehabilitation programme alone, BM (but not adipose-derived) MSC treatment was associated with an increased odds of returning to racing, with at least five races post-injury. It was acknowledged that the treatment group receiving adipose-derived MSC included a limited number of horses compared with BM-MSC, and that due to the retrospective nature of the study, it was not possible to determine how strictly rehabilitation protocols were followed in every case. Finally, in the sixth paper in our series, Murphy et al. (2022) compared the post-injury performance of Thoroughbred and Standardbred racehorses diagnosed with SDFT tendonitis treated with intralesional bone marrow and superior check desmotomy or managed conservatively and further to compare this performance with that of uninjured racehorses matched for age, sex and number of starts pre-injury.24 BMAC is available as a minimally manipulated alternative to cultured cells, which contains concentrations of MSCs and interleukin receptor antagonist protein higher than that in serum, distinguishing it from other orthobiologic products.25 Bone marrow aspirate may be appropriate to deliver autologous anabolic molecules, stromal cells and scaffold in the treatment of osteoarthritis, desmitis, and articular cartilage or bone defects.25 In this study, horses that received the combination surgical intervention and bone marrow treatment were found to be more likely to return to racing than those managed conservatively, although of those that returned to racing in both groups, there was no difference in the average number of placings, wins or post-injury earnings between those surgically treated versus conservatively managed. While these findings support a potential beneficial effect for intralesional bone marrow injection, this treatment was only evaluated in combination with surgical intervention, and therefore the direct effect of the bone marrow aspirate therapy alone cannot be ascertained. Immune licensing of MSC to enhance immunomodulatory and antimicrobial properties: The heterogeneity within and between stromal cell populations has been proposed to be partially responsible for the observed variability in therapeutic responses.26 Pre-activation or 'inflammatory licensing' of MSC through priming with various cytokines or agonists including TGF-ß, Toll- and Nod-like receptor agonists or selection for expression of integrin α10β1 has been described in a number of studies as a means to generate a homogeneous population of immunomodulatory MSCs, and thereby potentially improve the consistency of MSC therapy and response to treatment.7, 8, 19, 27-34 In the seventh paper in our series, Broeckx et al. (2019) built on these concepts to evaluate the use of chondrogenic-induced MSC to treat osteoarthritis in a randomised, double-blinded, placebo-controlled proof-of-concept study.35 Osteoarthritis was induced in the metacarpophalangeal joint using an osteochondral fragment-groove model and horses received intra-articular injection with allogeneic chondrogenic-induced MSC and equine allogeneic plasma or 0.9% saline at 5 weeks postoperatively. Improvement in visual and objective lameness was seen with MSC intervention compared with control. Cartilage oligomeric matrix protein, collagen type II and glycosaminoglycans were elevated in the articular cartilage of horses receiving MSCs. Synovial fluid displayed higher viscosity and lower glycosaminoglycan levels in the MSC-treated group. Other synovial fluid biomarkers or cytology parameters did not differ between groups. Importantly, no adverse events or drug reactions were noted. These authors concluded that allogeneic equine chondrogenic-induced MSC combined with equine plasma may be a promising treatment for osteoarthritis in horses. In the eighth paper in our series, this investigative group furthered the field in MSC licensing to evaluate allogeneic tenogenic primed MSC (tpMSC) in a clinical field study in horses with naturally occurring SDFT and suspensory ligament (SL) injuries in Carlier et al. (2023).36 In this multi-centre, blinded, randomised, placebo-controlled clinical trial, 100 client-owned horses with SDFT and SL injuries received either intralesional tpMSC or saline injections, and clinical and ultrasonographic evaluations were performed at the time of injection and subsequently at days 56 and 112. Horses receiving tpMSC treatment achieved improvement in fibre alignment scores and echogenicity and lesion size was

Subjects

MeSH terms (MEDLINE)

Horse DiseasesHorsesAnimalsVeterinary MedicineRegenerative MedicinePeriodicals as Topic

Author keywords

biologichorseregenerativetherapy

Authors and institutions

  • Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA.

ORCID profiles: Lynn Pezzanite

Cite

APA

Pezzanite, L. (2024). Clinical insights: Regenerative therapies in equine practice: Top 10 EVJ papers 2019–2024. Equine Veterinary Journal. https://doi.org/10.1111/evj.14136

Vancouver

Pezzanite L. Clinical insights: Regenerative therapies in equine practice: Top 10 EVJ papers 2019–2024. Equine Veterinary Journal. 2024. doi:10.1111/evj.14136

BibTeX
@article{Pezzanite2024,
  author = {Pezzanite, Lynn},
  title = {Clinical insights: Regenerative therapies in equine practice: Top 10 EVJ papers 2019–2024},
  journal = {Equine Veterinary Journal},
  year = {2024},
  doi = {10.1111/evj.14136}
}
Start for free →